Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant
Share
Why It Matters
Celcuity's cancer medicine showed strong results in patient testing. When doctors see good safety and effectiveness data, they watch for the company's next steps forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.